Kypha acquires Biosensia—expands first-in-class immune status monitoring platforms

Kypha, a medical diagnostics company developing specialized biomarker testing solutions for precision monitoring of immune status and inflammation, has acquired Biosensia, a diagnostics platform and contract development company that strengthens Kypha’s product commercialization. This acquisition demonstrates Kypha’s commitment to meet the need for universally accessible, reliable and timely immune status results in virtually any setting from acute hospital care, to centralized laboratories, physician offices and home use.

The combined first-in-class platforms promise to quickly and accurately detect meaningful changes in immune-mediated disease activity for more effective treatment decisions and patient care.

Kypha’s innovative diagnostics platforms measure Complement and other important immune status biomarkers accurately, and reliably. Kypha’s Comp act testing platform, analytically validated and GMP-manufactured, includes a small portable instrument with multiple single-use rapid assay cassettes designed to quantitatively measure complement activation biomarkers, from a small volume of blood in either laboratory or point-of-care settings. Biosensia’s RapiPlex is a proprietary diagnostic system designed to support CLIA-waived protocols and is capable of producing laboratory quality quantitative and qualitative results with a disposable cartridge for up to 24 analytes in a multiplex format.

The proprietary technologies and core competencies of each company are perfectly synergistic. Blending them enhances and accelerates the delivery of our products to health care practitioners, researchers and pharmaceutical companies seeking to more precisely assess and monitor immune status dynamics. The addition of Biosensia’s EU-based ISO-certified facilities and deeply experienced core team allows us to bring product development, quality control and test manufacturing in house and continue to provide contract assay development and manufacturing services to Biosensia clients around the world,” according to Chad Stiening, PhD, Chief Executive Officer, Kypha.

We are very excited about bringing our advanced platform together with Kypha’s specialized biomarker testing and achieve the clinical impact that we designed RapiPlex to fulfill,” stated Niamh O’Luanaigh, Chief Operating Officer, Biosensia.

With continued growth in biologic and cellular therapies targeting complement- and immune-mediated mechanisms, the need for these solutions is growing rapidly. This acquisition reinforces our position as the ideal diagnostic partner for stratifying patient populations and tailoring treatment for each patient suffering from immune mediated conditions,” enthused Martin Schmidt, PhD, Chief Scientific Officer, Kypha.